

FORM AOC - 1

Pursuant to first proviso to sub-section (3) of section 129 of Companies Act, 2013 with the Rule 5 of Companies (Accounts) Rules, 2014
Statement containing salient features of the financial statement of subsidiaries / associate companies/ joint ventures

PART "A": Subsidiaries															₹ in Million
Sr No	Name of the Subsidiary Company	Date of acquisition of subsidiary	Reporting Currency	Rate	Capital	Reserve	Total Assets	Total Liabilities	Investment Other than Investment in Subsidiary	Turnover	Profit / (Loss) before Taxation	Provision for Taxation	Profit / (Loss) after Taxation	Proposed Dividend	% of Shareholding
1	Green Eco Development Centre Limited	12.11.2010	INR	1.00	7.0	(7.0)	1.5	1.5	-	-	(0.9)	-	(0.9)	-	100.00%
2	Sun Pharmaceutical (Bangladesh) Limited	29.03.2001	BDT	0.89	53.3	1,752.7	2,703.9	897.9	-	1,942.6	517.3	213.7	303.6	-	72.50%
3	Sun Pharmaceutical Industries, Inc.	14.06.2011	USD	75.43	-	56,727.1	127,512.5	70,785.4	9,827.8	57,272.4	5,251.7	2,633.2	2,618.5	-	100.00%
4	Sun Farmaceutica do Brasil Ltda.	22.05.2009	BRL	14.52	80.9	(2,753.5)	946.1	3,618.7	-	1,629.5	(600.0)	47.6	(647.6)	-	100.00%
5	Sun Pharma De Mexico S.A. DE C.V.	03.12.2002	MXN	3.15	3.2	977.9	1,056.4	75.3	-	951.3	205.2	58.6	146.6	-	75.00%
6	SPIL De Mexico S.A. DE C.V.	13.02.2002	MXN	3.15	0.2	-	0.2	-	-	-	-	-	-	-	100.00%
7	Sun Pharmaceutical Peru S.A.C.	27.06.2006	PEN	21.94	-	(170.5)	0.3	170.8	-	-	1.7	-	1.7	-	99.33%
8	OOO "Sun Pharmaceutical Industries" Limited	12.11.2007	RUB	0.96	-	(159.4)	20.2	179.6	-	-	8.1	2.5	5.6	-	100.00%
9	Sun Pharma De Venezuela, C.A.	06.11.2011	VES	0.00	-	-	-	-	-	-	-	-	-	-	100.00%
10	Chatterm Chemicals Inc.	24.11.2008	USD	75.43	2,597.3	1,277.5	3,956.6	81.8	-	2,190.0	434.9	145.0	289.9	-	100.00%
11	The Taro Development Corporation	20.09.2010	USD	75.43	-	8,855.2	8,787.6	(67.6)	-	-	(8,324.1)	(1,995.4)	(6,328.7)	-	100.00%
12	Alkaloida Chemical Company Zrt.	05.08.2005	USD	75.43	6,732.9	45,552.5	52,893.1	607.7	339.4	2,824.7	399.8	31.0	368.8	-	99.99%
13	Sun Pharmaceutical Industries (Australia) Pty Limited	11.03.2008	AUD	46.49	3,237.6	(2,522.3)	6,863.0	6,147.7	-	4,125.2	(395.0)	-	(395.0)	-	100.00%
14	Aditya Acquisition Company Ltd.	22.04.2007	ILS	21.21	-	10.9	17.1	6.2	-	22.8	(3.9)	1.5	(5.4)	-	100.00%
15	Sun Pharmaceutical Industries (Europe) B.V.	29.06.2007	EURO	82.93	1.5	31.5	1,441.6	1,408.6	-	2,893.2	37.3	8.0	29.3	-	100.00%
16	Sun Pharmaceuticals Germany GmbH	11.08.2008	EURO	82.93	2.1	(146.0)	1,670.1	1,814.0	-	2,266.1	27.7	9.1	18.6	-	100.00%
17	Sun Pharmaceuticals France	10.02.2009	EURO	82.93	3.1	6.9	11.4	1.4	-	8.8	38.9	-	38.9	-	100.00%
18	Sun Pharma Global FZE	25.11.2008	USD	75.43	311.1	65,751.4	109,870.6	43,808.1	3,405.2	12,819.9	(35,347.7)	-	(35,347.7)	-	100.00%
19	Sun Pharmaceuticals SA (Pty) Ltd	22.10.2008	ZAR	4.19	-	0.8	159.5	158.7	-	57.8	1.4	0.4	1.0	-	100.00%
20	Sun Laboratories FZE	13.03.2011	USD	75.43	924.1	(1,605.9)	24,683.8	25,365.6	-	8,513.0	(517.7)	-	(517.7)	-	100.00%
21	Sun Pharma Japan Ltd.	01.03.2012	JPY	0.70	109.9	1,576.9	7,579.9	5,893.1	-	2,283.6	(553.0)	114.1	(667.1)	-	100.00%
22	Sun Pharma Philippines, Inc.	08.12.2011	PHP	1.48	12.8	(556.8)	380.7	924.7	-	506.0	29.3	4.9	24.4	-	100.00%
23	Sun Pharmaceuticals Korea Ltd.	20.09.2011	KRW	0.06	6.2	(2.4)	6.2	2.4	-	-	(0.4)	-	(0.4)	-	100.00%
24	Caraco Pharmaceuticals Private Limited	12.01.2012	INR	1.00	0.1	(0.2)	-	0.1	-	-	(0.1)	-	(0.1)	-	100.00%
25	Sun Pharma Laboratories Limited	09.03.2012	INR	1.00	400.5	204,817.8	221,472.5	16,254.2	695.9	68,541.1	19,013.5	2,796.2	16,217.3	-	100.00%
26	Morley & Company, Inc.	05.05.1983	USD	75.43	0.2	2.9	3.1	-	-	-	(2.8)	(0.7)	(2.1)	-	100.00%
27	Taro Pharmaceutical Industries Ltd. (Taro)	20.09.2010	USD	75.43	51.3	158,643.1	163,340.5	4,646.1	7,440.9	19,185.2	18,582.5	159.4	18,423.1	-	77.10%
28	Taro Pharmaceuticals Inc.	20.09.2010	USD	75.43	28,105.8	107,666.6	140,963.0	5,190.6	71,566.4	26,839.7	15,902.9	4,219.2	11,683.7	-	77.10%
29	Taro Pharmaceuticals U.S.A., Inc.	20.09.2010	USD	75.43	10.9	(451.3)	35,249.4	35,689.8	573.1	36,533.0	553.7	(192.8)	746.5	-	77.10%
30	Taro Pharmaceuticals North America, Inc.	20.09.2010	USD	75.43	-	28,110.9	28,111.0	0.1	-	-	(1.0)	-	(1.0)	-	77.10%
31	Taro Pharmaceuticals Europe B.V.	20.09.2010	EURO	82.93	1.5	0.2	4.8	3.1	-	-	0.3	-	0.3	-	77.10%
32	Taro International Ltd.	20.09.2010	USD	75.43	-	1,302.0	1,596.3	294.3	-	2,057.2	350.9	79.9	271.0	-	77.10%
33	Dusa Pharmaceuticals, Inc.	19.12.2012	USD	75.43	0.8	11,818.5	15,211.9	3,392.6	-	7,864.0	450.3	(105.5)	555.8	-	100.00%
34	Mutual Pharmaceutical Company Inc.	05.02.2013	USD	75.43	0.1	9,917.2	10,913.7	996.4	-	3,112.8	305.6	160.4	145.2	-	100.00%

FORM AOC - 1

Pursuant to first proviso to sub-section (3) of section 129 of Companies Act, 2013 with the Rule 5 of Companies (Accounts) Rules, 2014
Statement containing salient features of the financial statement of subsidiaries / associate companies/ joint ventures

PART "A": Subsidiaries															₹ in Million
Sr No	Name of the Subsidiary Company	Date of acquisition of subsidiary	Reporting Currency	Rate	Capital	Reserve	Total Assets	Total Liabilities	Investment Other than Investment in Subsidiary	Turnover	Profit / (Loss) before Taxation	Provision for Taxation	Profit / (Loss) after Taxation	Proposed Dividend	% of Shareholding
35	Faststone Mercantile Company Private Limited	01.04.2012	INR	1.00	0.1	12.9	13.0	-	-	-	0.4	0.1	0.3	-	100.00%
36	Neethav Real Estate Private Limited	01.04.2012	INR	1.00	0.1	2,922.3	3,078.1	155.7	-	1.6	1.5	0.4	1.1	-	100.00%
37	Realstone Multitrade Private Limited	01.04.2012	INR	1.00	0.1	12.0	12.1	-	-	-	0.4	0.1	0.3	-	100.00%
38	Skisen Labs Private Limited	01.04.2012	INR	1.00	163.6	(163.8)	0.1	0.3	0.0	-	(0.1)	-	(0.1)	-	100.00%
39	Softdeal Trading Company Private Limited	01.04.2012	INR	1.00	0.1	11.0	11.1	-	-	-	(0.1)	-	(0.1)	-	100.00%
40	Universal Enterprises Private Limited	31.08.2012	INR	1.00	4.5	0.8	8.3	3.0	-	-	(0.1)	-	(0.1)	-	100.00%
41	Sun Pharma Switzerland Ltd.	10.06.2013	CHF	78.24	7.8	1.5	10.9	1.6	-	40.8	(1.7)	-	(1.7)	-	100.00%
42	Sun Pharma Holdings	06.08.2015	USD	75.43	258,034.2	(21,432.8)	237,520.7	919.3	-	-	(44.5)	-	(44.5)	-	100.00%
43	Pharmalucence, Inc.	15.07.2014	USD	75.43	-	7,296.1	9,110.6	1,814.5	-	3,015.6	846.2	44.2	802.0	-	100.00%
44	PI Real Estate Ventures, LLC	15.07.2014	USD	75.43	-	2,417.8	1,318.4	(1,099.4)	-	226.3	172.1	-	172.1	-	100.00%
45	Sun Pharma East Africa Limited	13.06.2014	KES	0.72	0.1	(99.4)	411.1	510.4	-	536.0	17.8	6.7	11.1	-	100.00%
46	Basics GmbH	24.03.2015	EURO	82.93	404.3	503.9	8,055.3	7,147.1	-	3,840.1	77.6	24.8	52.8	-	100.00%
47	"Ranbaxy Pharmaceuticals Ukraine" LLC	24.03.2015	UAH	2.74	109.3	194.2	417.8	114.3	-	1,015.8	68.9	12.6	56.3	-	100.00%
48	Sun Pharmaceuticals Morocco LLC	24.03.2015	MAD	7.48	91.5	(88.5)	2,105.2	2,102.2	-	1,554.9	84.3	39.4	44.9	-	100.00%
49	Sun Pharmaceutical Industries S.A.C.	24.03.2015	PEN	21.94	95.3	(257.6)	523.8	686.1	-	596.0	17.5	-	17.5	-	100.00%
50	Ranbaxy Holdings (U.K.) Limited	24.03.2015	GBP	93.02	2,842.3	142.6	2,985.5	0.6	-	-	(0.6)	-	(0.6)	-	100.00%
51	Sun Pharma France (Formerly known as Ranbaxy Pharmacie Genériques)	24.03.2015	EURO	82.93	2,068.9	(4,973.9)	1,123.8	4,028.8	-	2,242.5	(248.1)	-	(248.1)	-	100.00%
52	Office Pharmaceutique Industriel Et Hospitalier	24.03.2015	EURO	82.93	110.3	(3.1)	252.8	145.6	-	375.5	1.5	-	1.5	-	100.00%
53	Ranbaxy Italia S.P.A.	24.03.2015	EURO	82.93	4.1	27.7	1,887.2	1,855.4	-	2,640.0	39.1	22.2	16.9	-	100.00%
54	Ranbaxy Pharmaceuticals (Pty) Ltd	24.03.2015	ZAR	4.19	838.0	809.4	2,778.8	1,131.4	-	3,912.1	162.2	-	162.2	-	100.00%
55	Ranbaxy South Africa (Pty) Ltd	24.03.2015	ZAR	4.19	73.4	882.5	1,953.7	997.8	-	3,387.0	72.7	21.0	51.7	-	100.00%
56	Sun Pharma Egypt Limited LLC (Formerly known as Ranbaxy Egypt Ltd)	24.03.2015	EGP	4.77	628.9	(368.7)	646.4	386.2	-	484.9	(61.6)	(18.1)	(43.5)	-	100.00%
57	Rexcel Egypt LLC	24.03.2015	EGP	4.77	10.0	(33.0)	6.0	29.0	-	-	(2.9)	-	(2.9)	-	100.00%
58	Ranbaxy (U.K.) Limited	24.03.2015	GBP	93.02	2,023.2	(491.4)	2,781.6	1,249.8	-	2,780.8	91.1	20.9	70.2	-	100.00%
59	Ranbaxy (Poland) SP Z O.O.	24.03.2015	PLN	18.19	78.0	143.0	316.4	95.4	-	563.5	26.4	8.0	18.4	-	100.00%
60	Ranbaxy Nigeria Limited	24.03.2015	NGN	0.21	8.3	(383.6)	1,819.7	2,195.0	-	1,171.0	(264.4)	5.9	(270.3)	-	86.16%
61	Ranbaxy (Thailand) Co., Ltd.	24.03.2015	THB	2.30	264.2	(51.0)	1,037.3	824.1	-	1,678.9	(18.0)	-	(18.0)	-	100.00%
62	Ohm Laboratories, Inc.	24.03.2015	USD	75.43	18.0	2,888.7	10,467.5	7,560.8	-	11,468.2	(1,358.1)	(51.4)	(1,306.7)	-	100.00%
63	Ranbaxy Signature LLC	24.03.2015	USD	75.43	-	992.4	992.4	-	-	539.0	307.2	-	307.2	-	67.50%
64	Ranbaxy Inc.	24.03.2015	USD	75.43	980.6	2,896.7	4,432.9	555.6	-	-	(1,238.3)	42.3	(1,280.6)	-	100.00%
65	Ranbaxy Ireland Limited	24.03.2015	EURO	82.93	589.7	(12.6)	577.2	0.1	-	-	(3.3)	-	(3.3)	-	100.00%
66	AO Ranbaxy	24.03.2015	RUB	0.96	157.0	988.6	5,722.4	4,576.8	-	4,820.9	9.9	7.9	2.0	-	100.00%

FORM AOC - 1

Pursuant to first proviso to sub-section (3) of section 129 of Companies Act, 2013 with the Rule 5 of Companies (Accounts) Rules, 2014
Statement containing salient features of the financial statement of subsidiaries / associate companies/ joint ventures

PART "A": Subsidiaries															₹ in Million
Sr No	Name of the Subsidiary Company	Date of acquisition of subsidiary	Reporting Currency	Rate	Capital	Reserve	Total Assets	Total Liabilities	Investment Other than Investment in Subsidiary	Turnover	Profit / (Loss) before Taxation	Provision for Taxation	Profit / (Loss) after Taxation	Proposed Dividend	% of Shareholding
67	Sun Pharma Laboratorios, S.L.U (formerly Laboratorios Ranbaxy, S.L.U.)	24.03.2015	EURO	82.93	82.9	428.6	1,478.4	966.9	-	2,442.6	60.2	-	60.2	-	100.00%
68	Ranbaxy (Malaysia) SDN. BHD.	24.03.2015	MYR	17.48	145.1	827.2	2,082.1	1,109.8	-	2,887.2	741.0	179.2	561.8	-	95.67%
69	Ranbaxy Farmaceutica Ltda.	24.03.2015	BRL	14.52	252.2	(1,633.5)	1,703.5	3,084.8	-	1,958.3	(328.2)	43.2	(371.4)	-	100.00%
70	Sun Pharma ANZ Pty Ltd	24.03.2015	AUD	46.49	808.9	(939.3)	1,537.9	1,668.3	-	2,226.6	121.4	-	121.4	-	100.00%
71	Sun Pharma Canada Inc. (Formerly known as Ranbaxy Pharmaceuticals Canada Inc.)	24.03.2015	CAD	53.19	119.7	89.3	1,003.6	794.6	-	1,319.1	(51.4)	-	(51.4)	-	100.00%
72	Terapia SA	24.03.2015	RON	17.15	428.7	6,283.3	11,929.9	5,217.9	-	13,132.9	2,853.5	375.3	2,478.2	-	96.81%
73	Sun Pharma (Netherlands) B.V. (Formerly known as Ranbaxy (Netherlands) B.V.)	24.03.2015	USD	75.43	45,381.0	20,201.1	66,162.3	580.2	3,180.8	6,440.4	6,040.9	(111.0)	6,151.9	-	100.00%
74	Insite Vision Incorporated	02.11.2015	USD	75.43	-	(443.9)	276.1	720.0	-	681.2	74.6	(26.5)	101.1	-	100.00%
75	JSC Biosintez	19.12.2016	RUB	0.96	0.3	185.7	4,019.8	3,833.8	1.9	2,335.0	46.7	63.1	(16.4)	-	100.00%
76	Sun Pharmaceutical Holdings USA, Inc	18.11.2016	USD	75.43	-	63,997.2	63,997.2	-	-	-	521.1	-	521.1	-	100.00%
77	Foundation for Disease Elimination and Control of India	21.09.2016	INR	1.00	0.1	2.7	3.4	0.6	-	54.3	1.6	-	1.6	-	100.00%
78	Zenotech Laboratories Limited	27.07.2017	INR	1.00	610.3	(114.1)	855.5	359.3	-	259.4	107.8	-	107.8	-	57.56%
79	Sun Pharmaceutical Medicare Limited	16.01.2017	INR	1.00	2.5	(1,883.9)	3,834.1	5,715.5	-	799.2	(1,396.2)	0.1	(1,396.3)	-	100.00%
80	Pola Pharma Inc.	01.01.2019	JPY	0.70	69.6	5,029.4	8,341.7	3,242.7	-	7,714.2	899.1	206.0	693.1	-	100.00%
81	Kayaku Co., Ltd.	01.01.2019	JPY	0.70	76.5	2,025.4	3,532.9	1,431.0	-	4,140.3	3.9	23.4	(19.5)	-	100.00%
82	Sun Pharma Distributors Limited	19.03.2019	INR	1.00	1.5	673.3	22,930.4	22,255.6	-	81,369.9	903.6	229.2	674.4	-	100.00%
83	Realstone Infra Limited	31.01.2020	INR	1.00	2.5	(0.3)	2.5	0.3	-	-	(0.3)	-	(0.3)	-	100.00%

Note:

- 0.0' represents amount less than 0.05 Million and rounded off
- In respect of entities at Sr. Nos. 5 to 8, 47, 66, 74, 75 and 80 the reporting date is as of December 31, 2019 and different from the reporting date of the Parent Company.
- Entity at Sr. No. 83 has been incorporated during the year ended March 31, 2020.
- Foundation for Disease Elimination and Control of India (FDEC), a wholly owned subsidiary incorporated in India on September 21, 2016 by the Company as part of its Corporate Social Responsibility (CSR) initiative, has entered into an MOU with Indian Council of Medical Research (ICMR) and Madhya Pradesh State Government to undertake the Malaria Elimination Demonstration Project with a goal to eliminate Malaria in the state. FDEC is a Section 8 company not considered for consolidation since it can apply its income for charitable purposes only and can raise funds/contribution independently.
- Books of accounts and other related records/documents of the overseas subsidiaries of the Zenotech Laboratories Limited were missing and due to non-availability of those records/information, Zenotech Laboratories Limited is unable to prepare consolidated accounts.
- 3 Skyline LLC and One Commerce drive LLC are being consolidated with Taro Pharmaceuticals U.S.A., Inc.
- The above does not include Taro Pharmaceutical Laboratories Inc., 2 Independence Way LLC, URL PharmaPro LLC and Dungan Mutual Associates LLC as they have no operation and does not have any Assets, Liabilities or Equity as on the close of their financial year.
- Pola Pharma Inc. has been merged with Sun Pharma Japan Ltd. with effect from January 01, 2020. Consequently, the numbers against Pola Pharma Inc. are for the period January 01, 2019 to to December 31, 2019.
- Financial statements of Kayaku Co. Ltd. are for the period January 01, 2019 to March 31, 2020 as it has changed its Financial year end from December to March.
- With effect from March 27, 2020 Morley & Company, Inc has been merged with The Taro Development Corporation.
- With effect from January 25, 2019 Sun Global Canada Pty. Ltd. has been dissolved.
- With effect from February 27, 2020 Sun Global Development FZE has been dissolved.
- With effect from January 28, 2020 Sun Pharma Healthcare FZE has been dissolved.
- Sonke Pharmaceuticals Proprietary Limited have been consolidated with Ranbaxy South Africa (Pty) Ltd.
- With effect from March 16, 2020 Dungan Mutual Associates, LLC and URL PharmaPro, LLC has been merged with Mutual Pharmaceutical Company Inc.

FORM AOC - 1

Pursuant to first proviso to sub-section (3) of section 129 of Companies Act, 2013 with the Rule 5 of Companies (Accounts) Rules, 2014

Statement containing salient features of the financial statement of subsidiaries / associate companies/ joint ventures

₹ in Million

Part "B": Associate Companies and Joint Venture						
Sr. No	Name of Associates/Joint Venture	Joint Venture		Associate		
		Artes Biotechnology GmbH	Generic Solar Power LLP	Trumpcard Advisors and Finvest LLP	Medinstill LLC	Tarsius Pharma Ltd.
1	Latest Balance Sheet Date	31-Dec-19	31-Mar-20	31-Mar-20	31-Dec-19	31-Dec-19
	Date of acquisition	13.02.2014	09.10.2015	31.03.2017	13.03.2014	10.09.2018
2	Shares of Associate/Joint Ventures held by the company on the year end					
	No.	15,853	28,760	NA	1,999	345,622
	Amount of Investment in Associates/Joint Venture	262.0	0.0	579.0	1,389.2	195.2
	Extend of Holding %	45.00%	28.76%	40.61%	19.99%	18.33%
3	Description of how there is significant influence	NA	NA	NA	NA	NA
4	Reason why the associate/joint venture is not consolidated	NA	NA	NA	NA	NA
5	Networth attributable to Shareholding as per latest Balance Sheet	51.1	0.0	376.1	(930.5)	23.1
6	Profit / (loss) for the year					
	i. Considered in Consolidation	(10.0)	(0.0)	128.2	(247.8)	(18.7)
	ii. Not Considered in Consolidation	(12.2)	(0.0)	187.5	(991.8)	(83.3)

For and on behalf of the Board of Directors of
Sun Pharmaceutical Industries Limited

DILIP S. SHANGHVI

Managing Director
(DIN: 00005588)

SAILESH T. DESAI

Wholetime Director
(DIN: 00005443)

SUNIL R. AJMERA

Company Secretary

C. S. MURALIDHARAN

Chief Financial Officer
Mumbai, May 27, 2020